Projects per year
A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Dose, Safety and Pharmacokinetic / Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of Decarboxylase Inhibitor to L-dopa Responsive Parkinson's Disease Patients.
15/03/18 → 15/03/20
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma who are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2).
17/05/19 → 31/05/23
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1).
Roberts, S. & Lewis, P.
24/01/19 → 30/04/23
A Phase III, Randomized, Double-blind, Placebo-Controlled, Multicenter study to Evaluate the Efficacy and Safety of Baloxavir Marboxil in Combination with Standard of Care Neuraminidase Inhibitor in Hospitalized Patients with Severe Influenza.
Cheng, A. & Roney, J.
15/11/18 → 15/05/21
A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae
Chen, M. & Silvers, J.
19/12/19 → 31/12/24
A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhoea Caused by Neisseria gonorrhoeae.
10/10/19 → 31/12/20
A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA).
Voskoboynik, M. & Cross, N.
6/02/19 → 31/12/24
1/06/11 → 31/12/13
1/01/02 → 31/12/02
COBRRA: Apixaban Twice Daily vs Rivaroxaban Once Daily for the Treatment of Venous Thromboembolism: A randomised controlled trial
Chen, V., Castellucci, L., Brighton, T., Tran, H., Rodger, M., Le Gal, G., Kahn, S., Simes, R. J., Reddel, C. & Morton, R. L.
1/02/20 → 31/01/24
Gerondakis, S., Adams, J. M., Bouillet, P., Colman, P., Cory, S., Huang, D., Kluck, R., Lindeman, G., Strasser, A., Vaux, D. & Visvader, J.
1/01/12 → 31/12/16
A prospective, multicenter, observational, post-authorization safety study to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (Post Authorization Safety Study (PASS) Protocol).
31/07/19 → 31/12/24
A prospective, multi-national, non-interventional study in haemophilia A and B patients with or without inhibitors treated according to routine clinical treatment practice (explorer 6).
Tran, H. & Kennedy, N.
12/03/19 → 31/12/21
A Prospective, Non-Randomized Single-Arm Pilot Study to Assess the Safety and Effectiveness of Instylla HES For Transcatheter Embolization of Arterial Bleeds.
Goh, G. & Kavnoudias, H.
30/07/20 → 28/02/22
A prospective, observational study in patients receiving adjuvant Nivolumab therapy for resected melanoma in Australia.
Brady, B. & Lai, L. H.
12/12/19 → 1/12/21
A Prospective, Single-arm, Multicenter Study to Evaluate the Safety and Performance of the Instylla Hydrogel Embolic System (HES) For Patients Requiring Vascular Embolization Alone or in the Pre-operative Setting for Treatment of Malignant and Benign Hypervascular Tumors, and Select Non-Traumatic End-Organ Infarct.
3/06/19 → 31/12/24
A Prospective Non-Interventional Study of Bleeding Episodes, Factor VIII Infusions, and Patient-Reported Outcomes in Individuals with Severe Hemophilia A.
Tran, H. & Kennedy, N.
10/01/19 → 31/12/24
A prospective observational study of the effects of a very low calorie diet on liver volume and intra-abdominal fat mass in the severely obese
1/01/05 → 31/12/05
A prospective pilot observational study of blood product transfusion practices in Australian Intensive Care Units
Cooper, J. & Syres, G.
1/08/08 → 30/11/08
A prospective study of the pathogenesis and management of minimal hepatic encephalopathy (MHE) in cirrhotics
11/06/13 → 10/06/16
Ting, S. B.
1/01/07 → 31/12/11
A randomised, double-blind, placebo-controlled, parallel-group, 52 week study to evaluate the efficacy and safety of oral DHEA therapy in postmenopausal women of sexual function wellbeing and vasomoto
10/11/06 → 9/11/07
A randomised, double blinded, controlled study of percutaneous transluminal angioplasty for extracranial and ayzgos vein stenoses in patients with multiple sclerosis
Thomson, K. & Kavnoudias, H.
1/01/13 → 31/12/14
A Randomised, Double-Blind Study to Compare the Efficacy of Treatment with Denosumab versus Alendronate Sodium in Postmenopausal Women with Low Bone Mineral Density
Davis, S. & Papalia, M.
1/07/06 → 30/06/07
A randomised controlled trial of daily antibacterial mouthwash to reduce pharyngeal gonorrhoea among men who have sex with men (MSM)
1/01/17 → 31/12/19
A randomised controlled trial of Focal Electrically Administered Seizure Therapy (FEAST) in patients with severe depression
Loo, C., Martin, D., Fitzgerald, P., Dokos, S., Hadzi-Pavlovic, D., George, M., Bai, S. & Boonstra, T.
1/01/19 → 31/12/23
A randomised controlled trial of NMDA antagonist, memantine, for the treatment of borderline personality disorder
Kulkarni, J. & Plebanski, M.
1/01/17 → 31/12/19
2/01/07 → 31/12/10
A randomised control trial of medical treatment versus the placement of the Lap Band in severely obese adolescents ; ID: 384215
1/01/06 → 31/12/08
Wei, A., Bradstock, K., Levis, M., Murray, M. & Roberts, A.
1/01/13 → 31/12/17
A randomised trial of allowing men who have sex with men to have HIV and syphilis tests between clinic consultations.
1/01/15 → 24/11/18
A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching from Treatment with 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment.
16/04/19 → 31/12/24
A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis.
Glaspole, I., Thien, F. & Symons, K. M.
1/05/20 → 31/12/21
A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy
Perkins, A., Leahy, M. F., Ross, D., Prasad, R. & Kennedy, N.
5/02/20 → 31/12/25